- Conditions
- Solid Tumors
- Interventions
- OPB-111077
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2593–2616
of 5,329
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg
- Drug
- Lead sponsor
- Human Genome Sciences Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 52 more
- Conditions
- Myelodysplastic Syndrome
- Interventions
- AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)
- Drug
- Lead sponsor
- Arno Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Elsubrutinib, Placebo for Elsubrutinib, Upadacitinib, Placebo for Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Alamitos, California + 18 more
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Binimetinib, Docetaxel, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
- Drug · Other · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Carfilzomib, Dexamethasone, Lenalidomide (Control)
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Detroit, Michigan
- Conditions
- Advanced Non-hematologic Malignancies, Advanced Metastatic Melanoma
- Interventions
- TAK-733
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Detriot, Michigan • Buffalo, New York
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Complications
- Interventions
- Device specific training, Study clinician/educator visit
- Device · Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • The Bronx, New York
- Conditions
- Labor Onset and Length Abnormalities, Induced; Birth
- Interventions
- Dilapan, Misoprostol
- Device · Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 307 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- New York, New York • Galveston, Texas
- Conditions
- Pain, Neoplasm, Cancer
- Interventions
- Tapentadol in the Titration Phase, Morphine in the Maintenance Phase, Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase, Tapentadol in the Maintenance Phase, Morphine in the Titration Phase
- Drug
- Lead sponsor
- Grünenthal GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 7
- States / cities
- St. Petersburg, Florida • Elkhart, Indiana • Shreveport, Louisiana + 4 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- QCC374
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Neuroendocrine Carcinoma, Neuroendocrine Tumors
- Interventions
- Seneca Valley Virus-001 (SVV-001), Nivolumab, Ipilimumab
- Biological · Drug
- Lead sponsor
- Peter Hosein, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions
- Talquetamab, Mezigdomide, Dexamethasone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Aging
- Interventions
- Esmolol infusion, Saline infusion, Pre exercise baseline, Isometric handgrip exercise, Semi-recumbent cycling
- Drug · Other
- Lead sponsor
- David N. Proctor, PhD
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Mesothelioma
- Interventions
- Nintedanib, Pemetrexed, Cisplatin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • San Francisco, California • Littleton, Colorado + 7 more
- Conditions
- Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
- Interventions
- TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Td vaccine, autologous HSCs, Pembrolizumab
- Biological · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 4 Years to 30 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Gainesville, Florida
- Conditions
- Sickle Cell Disease
- Interventions
- Busulfan, Fludarabine, r-ATG, Hematopoietic Cell Transplant, Tacrolimus, Methotrexate, Standard of Care, Alemtuzumab, Total Body Irradiation (TBI), Sirolimus, Melphalan, G-CSF
- Drug · Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 35
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more
- Conditions
- Neuroendocrine Tumors, Gastrointestinal Neoplasms, Carcinoid Tumors
- Interventions
- Lanreotide, Y-90 microspheres
- Drug · Device
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Kansas City, Missouri • Nashville, Tennessee
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic, Stroke, Cerebrovascular
- Interventions
- Reactive balance training with Neuromuscular Electrical Stimulation, Reactive balance training without Neuromuscular Electrical Stimulation
- Behavioral
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Uveitis
- Interventions
- Mycophenolate mofetil, Methotrexate, Prednisone
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Portland, Oregon
- Conditions
- Postpartum Depression
- Interventions
- ZULRESSO®
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Culver City, California • Miramar, Florida • Pompano Beach, Florida + 2 more
- Conditions
- Systemic Juvenile Idiopathic Arthritis With Active Flare
- Interventions
- canakinumab, placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 19 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
- Conditions
- Premature Birth
- Interventions
- Tummy time and parent education, Parent education only
- Behavioral
- Lead sponsor
- University of Indianapolis
- Other
- Eligibility
- 35 Weeks to 44 Weeks
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois